NEW YORK (GenomeWeb) – Private investment firms Ampersand Capital Partners and 1315 Capital announced today that they have partnered with a management group to acquire the commercial laboratory of Novartis subsidiary Genoptix.
Registering provides access to this and other free content.
Already have an account?Login Now.
This webinar will present an in-depth look at how Memorial Sloan Kettering Cancer Center has developed and implemented a next-generation sequencing panel for mutational tumor profiling of advanced cancer patients.
This webinar will be a roundtable discussion on the adoption of a commercial gene panel for tumor profiling at several leading US cancer centers.
This webinar will discuss the benefits of genomically profiling the immune microenvironment of soft tissue sarcomas during neoadjuvant therapy.